Today's biotech news includes the Medicare director offering a tempered view of TrumpRx and high-dose Wegovy getting an FDA ...

This week on "The Readout LOUD," a conversation with biotech "godfather" Stelios Papadapolous live from #STATBreakthrough.

In today's Morning Rounds newsletter, the highlights from #STATBreakthrough, a ruling against Kennedy’s gender-affirming care ...

Congress must fix the No Surprises Act before it bankrupts patients and employers, James Gelfand and Patricia Kelmar write.

The farm bill shows politicians catering to the agriculture industry risk losing the support of MAHA while running afoul of ...

A group of autism scientists kicked off efforts Thursday to influence Congress, and the research agendas of private ...

What's changed now is that there's a view in this administration that everything is political,” said Robert Califf, former ...

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about ...

Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based Synnovation Therapeutics.

Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective.

In recent years, a growing outcry has drawn long-overdue attention to a difficult truth: girls’ and women’s pain has too often been dismissed and undertreated in medicine. A 2022 study found that most ...

The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund research in the understanding and treatment of bipolar disorder and schizophrenia research.